Could pembrolizumab improve outcomes beyond standard of care for soft tissue sarcoma?

Results of the SU2C-SARC032 clinical trial have demonstrated that adding Keytruda® (pembrolizumab) to standard of care significantly improved disease-free survival for patients with advanced soft tissue sarcoma of the limb. In this interview, Yvonne Mowery (UPMC, PA, USA), provides an overview of how the team approached designing the trial for such a complex and rare cancer type. Additionally, she outlines next steps for the study, including monitoring for overall survival outcomes and correlative studies to identify which patients may benefit most from pembrolizumab. What are the key challenges in treating soft tissue sarcoma? The combination of surgery and radiation therapy...